Literature DB >> 29677514

Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation.

Mario Hofweber1, Saskia Hutten2, Benjamin Bourgeois3, Emil Spreitzer3, Annika Niedner-Boblenz4, Martina Schifferer5, Marc-David Ruepp6, Mikael Simons5, Dierk Niessing7, Tobias Madl3, Dorothee Dormann8.   

Abstract

Cytoplasmic FUS aggregates are a pathological hallmark in a subset of patients with frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS). A key step that is disrupted in these patients is nuclear import of FUS mediated by the import receptor Transportin/Karyopherin-β2. In ALS-FUS patients, this is caused by mutations in the nuclear localization signal (NLS) of FUS that weaken Transportin binding. In FTD-FUS patients, Transportin is aggregated, and post-translational arginine methylation, which regulates the FUS-Transportin interaction, is lost. Here, we show that Transportin and arginine methylation have a crucial function beyond nuclear import-namely to suppress RGG/RG-driven phase separation and stress granule association of FUS. ALS-associated FUS-NLS mutations weaken the chaperone activity of Transportin and loss of FUS arginine methylation, as seen in FTD-FUS, promote phase separation, and stress granule partitioning of FUS. Our findings reveal two regulatory mechanisms of liquid-phase homeostasis that are disrupted in FUS-associated neurodegeneration.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; FTD; Karyopherin-β2 (Kapβ2); Transportin (TNPO1); arginine methylation; fused in sarcoma (FUS); neurodegeneration; nuclear import; phase separation; stress granules

Mesh:

Substances:

Year:  2018        PMID: 29677514     DOI: 10.1016/j.cell.2018.03.004

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  179 in total

1.  The SH3 domain of Fyn kinase interacts with and induces liquid-liquid phase separation of the low-complexity domain of hnRNPA2.

Authors:  Joshua Amaya; Veronica H Ryan; Nicolas L Fawzi
Journal:  J Biol Chem       Date:  2018-11-05       Impact factor: 5.157

Review 2.  Protein arginine methylation: from enigmatic functions to therapeutic targeting.

Authors:  Qin Wu; Matthieu Schapira; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy
Journal:  Nat Rev Drug Discov       Date:  2021-03-19       Impact factor: 84.694

Review 3.  The molecular language of membraneless organelles.

Authors:  Edward Gomes; James Shorter
Journal:  J Biol Chem       Date:  2018-07-25       Impact factor: 5.157

4.  Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD.

Authors:  Hana M Odeh; James Shorter
Journal:  Emerg Top Life Sci       Date:  2020-12-11

Review 5.  Who's In and Who's Out-Compositional Control of Biomolecular Condensates.

Authors:  Jonathon A Ditlev; Lindsay B Case; Michael K Rosen
Journal:  J Mol Biol       Date:  2018-08-09       Impact factor: 5.469

Review 6.  Friend or foe-Post-translational modifications as regulators of phase separation and RNP granule dynamics.

Authors:  Mario Hofweber; Dorothee Dormann
Journal:  J Biol Chem       Date:  2018-12-26       Impact factor: 5.157

7.  Interaction hot spots for phase separation revealed by NMR studies of a CAPRIN1 condensed phase.

Authors:  Tae Hun Kim; Brandon J Payliss; Michael L Nosella; Ian T W Lee; Yuki Toyama; Julie D Forman-Kay; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

Review 8.  Liquid-Liquid Phase Separation and Its Mechanistic Role in Pathological Protein Aggregation.

Authors:  W Michael Babinchak; Witold K Surewicz
Journal:  J Mol Biol       Date:  2020-03-10       Impact factor: 5.469

Review 9.  Effect of additives on liquid droplets and aggregates of proteins.

Authors:  Kentaro Shiraki; Masahiro Mimura; Suguru Nishinami; Tomoto Ura
Journal:  Biophys Rev       Date:  2020-03-12

Review 10.  The Pathophysiology of Tau and Stress Granules in Disease.

Authors:  Anna Cruz; Mamta Verma; Benjamin Wolozin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.